The formation of the pre-B cell receptor (BCR) corresponds to an important checkpoint in B cell development that selects pro-B (pre-BI) cells expressing a functionally rearranged immunoglobulin μ (Igμ) heavy chain protein to undergo the transition to the pre-B (pre-BII) cell stage. The pre-BCR contains, in addition to Igμ, the surrogate light chains λ5 and VpreB and the signal transducing proteins Igα and Igβ. The absence of one of these pre-BCR components is known to arrest B cell development at the pre-BI cell stage. Disruption of the Pax5 gene, which codes for the B cell–specific activator protein (BSAP), also blocks adult B lymphopoiesis at the pre-BI cell stage. Moreover, expression of the mb-1 (Igα) gene and VH-to-DHJH recombination at the IgH locus are reduced in Pax5-deficient B lymphocytes ∼10- and ∼50-fold, respectively. Here we demonstrate that complementation of these deficiencies in pre-BCR components by expression of functionally rearranged Igμ and chimeric Igμ-Igβ transgenes fails to advance B cell development to the pre-BII cell stage in Pax5 (−/−) mice in contrast to RAG2 (−/−) mice. Furthermore, the pre-BCR is stably expressed on cultured pre-BI cells from Igμ transgenic, Pax5-deficient bone marrow, but is unable to elicit its normal signaling responses. In addition, the early developmental block is unlikely to be caused by the absence of a survival signal, as it could not be rescued by expression of a bcl2 transgene in Pax5-deficient pre-BI cells. Together, these data demonstrate that the absence of Pax5 arrests adult B lymphopoiesis at an early developmental stage that is unresponsive to pre-BCR signaling.
An important checkpoint in B cell development controls the transition from the pro-B (pre-BI) to the pre-B (pre-BII) cell stage that is initiated upon completion of a productive rearrangement at the immunoglobulin heavy chain (IgH) locus. A consequence of expressing the membrane-bound Igμ protein is the transient formation of the pre-B cell receptor (BCR).1 Signaling initiated by this receptor promotes allelic exclusion at the IgH locus, stimulates proliferative cell expansion, and induces differentiation to small pre-BII cells undergoing Ig light chain gene rearrangements (for review see reference 1). In addition to the Igμ protein, the pre-BCR consists of the two nonpolymorphic, surrogate light chains, λ5 and VpreB, as well as the signal transducing proteins Igα and Igβ whose expression is initiated early in B lymphopoiesis (for review see reference 2). B cell development is arrested at the pro-B (pre-BI) cell stage in mice that lack one component of either the pre-BCR (mIgμ [reference 3], λ5 [reference 4], and Igβ [reference 5]) or of the V(D)J recombination machinery [RAG1; reference 6), RAG2 (7), DNA-dependent protein kinase (DNA-PK; reference 8)]. However, expression of a functionally rearranged Igμ transgene is able to complement the recombination defects of both severe combined immunodeficiency (scid) and RAG mutant mice, thus resulting in pre-BCR formation and subsequent progression to the small pre-BII cell stage (9–11). The early expression of a rearranged Igμ transgene significantly shortens the duration of pro-B cell development by directly inducing differentiation to small pre-BII cells (12). Likewise, expression of a functionally rearranged κ light chain gene is capable of activating the pre-B cell transition in λ5-deficient mice (13, 14).
The Igα and Igβ proteins form a disulfide-linked heterodimer that is associated through its transmembrane domain with the Ig molecule in the pre-BCR and BCR. This heterodimer is not only essential for surface transport of Igs, but also constitutes the signal transducing unit of these receptors (for review see references 2, 15). The Igα and Igβ proteins both initiate signaling via immunoreceptor tyrosine-based activation motifs (ITAMs), which become phosphorylated upon receptor engagement and recruit intracellular effectors such as protein-tyrosine kinases to the receptor (2, 15). Apart from these motifs, the cytoplasmic tails of Igα and Igβ differ considerably in sequence, but yet appear to fulfill redundant functions in B cell development. Chimeric receptors, consisting of the Igμ protein fused to the cytoplasmic domain of either the Igα or Igβ protein, are each independently sufficient to induce the pre-B cell transition (16, 17) and to signal B cell maturation (18) in transgenic mice.
Insight into the transcriptional control of early B cell development has recently been gained by gene targeting in the mouse. One of the critical transcription factors thus implicated in early B lymphopoiesis is the B cell–specific activator protein (BSAP), which is encoded by the Pax5 gene (for review see references 19, 20). Pax5 is expressed from the earliest B lineage–committed precursor cell up to the mature B cell stage (21–23), and, consistent with this expression pattern, is essential for B lineage commitment in the fetal liver (24). However, in adult bone marrow, Pax5 is required later for the progression of B cell development beyond the early pro-B (pre-BI) cell stage (24, 25). Interestingly, the VH-to-DHJH recombination at the IgH locus is ∼50-fold reduced in Pax5-deficient pre-BI cells (24). Moreover, the mb-1 (Igα) gene, which has been identified as one of five direct BSAP (Pax5) targets, is expressed at an ∼10-fold lower level in these pre-BI cells, whereas Pax5 is not involved in the control of λ5, VpreB, and B29 (Igβ) expression (24, 26). Hence, the synthesis of two pre-BCR components, Igμ and Igα, is affected in early B lymphocytes of Pax5 mutant mice.
Here we have tested the hypothesis that the inability to express a pre-BCR might be the cause for the B cell developmental block in the bone marrow of Pax5-deficient mice. For this purpose, we have introduced functionally rearranged Igμ and chimeric Igμ–Igβ transgenes into the Pax5 mutant background. These transgenes were able to neither advance B cell development to the small pre-BII cell stage nor to elicit normal signaling responses, although the pre-BCR was expressed on the Igμ transgenic, Pax5-deficient pre-BI cells. Moreover, expression of a bcl2 transgene was also incapable of rescuing the early developmental block which is thus unlikely to result from the absence of a survival signal in Pax5 mutant B lymphocytes. These data therefore demonstrate that Pax5 fulfills an essential function during pro-B cell development before the pre-BCR stage.
Materials And Methods
The different mouse strains were maintained on the hybrid C56BL/6 × 129/Sv background. The genotype of Pax5 mutant mice (25) was determined by PCR analysis as previously described (24). RAG2 mutant mice (7) were genotyped by PCR amplification with the following oligonucleotides: 5′-GCAACATGTTATCCAGTAGCCGGT-3′ (primer 1), 5′-TTGGGAGGACACTCACTTGCCAGT-3′ (primer 2), and 5′-GTATGCAGCCGCCGCATTGCATCA-3′ (primer 3). A 605-bp PCR product was amplified from the wild-type RAG2 allele with primer pair 1 and 2 and a 1-kb DNA fragment from the mutant RAG2 allele with the pair 1 and 3. For simplicity, the mouse– human hybrid transgene mIgμ–Igβ (YS:VV; references 16, 27) is referred to as Igμ–Igβ in this manuscript and the functionally rearranged mouse Igμ transgene of the line M54 (28) as Igμ. The presence of the Igμ transgene expressing the membrane form of the μ heavy chain was detected by Southern blot analysis with radiolabeled pBR322 DNA as previously described (28). The Igμ–Igβ transgene was identified by PCR amplification with the primers 5′-GCCTTTGAGAACCTGTGGGC-3′ and 5′-CCTCATTCCTGGCCTGG-3′ (100-bp PCR product). The transgenic mouse strain Eμ-bcl-2-36 (29), which expresses a human bcl-2 cDNA under the control of the SV40 promoter and IgH Eμ enhancer in B and T lymphocytes (30), was genotyped by PCR using the primers 5′-GCAGACACTCTATGCCTGTGTGG-3′ and 5′-GGAACCTTACTTCTGTGGTGTGA-3′ (504-bp PCR product).
Pre-BI Cell Cultures.
Cell suspensions prepared from mouse bone marrow or fetal liver (at embryonic day 16.5 or 17.5) were plated at limiting dilutions on a semiconfluent layer of γ-irradiated stromal ST2 cells in the presence of IL-7–containing medium as previously described (24). After 1 wk of in vitro culture, individual pre-BI cell colonies were collected and further propagated as a cell pool. The long-term proliferation potential of these pre-BI cell pools was analyzed for at least 1 mo.
Antibodies and Flow Cytometry.
The following mAbs were purified from hybridoma supernatants on protein G–sepharose columns (Pharmacia Biotech AB, Uppsala, Sweden) and conjugated with sulfo-NHS-biotin (Pierce Chemical Co., Rockford, IL) as recommended by the suppliers: anti-c-kit mAb (ACK4; reference 31), anti-μ mAb (M41.42; reference 32), anti-λ5 mAb (LM34; reference 33), and anti-pre-BCR mAb (SL156; reference 33). The following reagents were purchased from PharMingen (San Diego, CA): biotinylated anti-CD25 mAb (7D4), biotinylated anti-CD43 mAb (S7), biotinylated anti-CD2 mAb (RM2-5), FITC- and PE-coupled anti-B220/CD45R mAb (RA3-6B2), FITC-conjugated anti-μ mAb (R6-60.2), APC-coupled anti– c-kit mAb (ACK45), purified anti–human Bcl-2 mAb (Bcl-2/ 100), and PE-conjugated streptavidin.
8–11-d-old mice were used for flow cytometric analysis, as older Pax5 mutant mice suffer from disease and generally die within 3 wk (25). Cultured pre-BI cells or single-cell suspensions prepared from the bone marrow of these mice were stained with different antibody combinations and subsequently analyzed on a FACScan® flow cytometer (Becton Dickinson, San Jose, CA) as previously described (25).
Intracellular Antibody Staining.
The cytoplasmic μ heavy chain protein was detected in bone marrow pre-BI cells as previously described (34). In brief, bone marrow cells were incubated with PE-coupled anti-B220 (RA3-6B2) and allophycocyanin (APC)- conjugated anti–c-kit (ACK45) antibodies at 4°C, washed twice with PBS, and then fixed with 2% paraformaldehyde (Fluka AG, Buchs, Switzerland) in PBS at room temperature for 20 min, followed by two washes with PBS. The fixed cells were subsequently permeabilized with 0.5% saponin (Sigma Chemical Co., St. Louis, MO) in 2% FCS/PBS and were simultaneously stained with FITC-conjugated anti-μ antibody (R6-60.2) for 40 min at 4°C, then washed twice in saponin buffer and once in 2% FCS/PBS before analysis on a FACSVantage® TSO flow cytometer (Becton Dickinson). Cultured bcl-2 transgenic, Pax5 (−/−) pre-BI cells were analyzed for expression of the human Bcl-2 protein by cytoplasmic staining with an anti–human Bcl-2 mAb (Bcl-2/100; detected with a PE-coupled goat anti–mouse IgG antibody) as described above.
Western Blot Analysis.
Whole cell extracts of in vitro cultured pre-BI cells were prepared by lysis in 0.25 M Tris, pH 7.5, and 0.1% Triton X-100, followed by removal of insoluble material by centrifugation. Total protein (10 μg) was separated by 10% SDS-PAGE, electrotransferred to a nitrocellulose membrane, and then incubated with a rabbit polyclonal anti-Igβ antiserum (27) (diluted at 1:1,000). Anti-Igβ antibodies were detected by enhanced chemiluminescence using a horseradish peroxidase–conjugated donkey anti–rabbit secondary antibody (ECL; Amersham International, Arlington Heights, IL).
RNase Protection Analysis.
A mouse terminal deoxynucleotidyl transferase (TdT) riboprobe was generated by inserting a 244-bp cDNA fragment of the mouse TdT mRNA (35) into the HindIII and EcoRI sites of pSP64. This cDNA fragment was amplified from RNA of 70Z/3 cells by reverse transcriptase PCR using the following primers: 5′-GCGGAATTCAAGGTGGATGCTCTCGACCAT-3′ and 5′-GCGAAGCTTCGTGGTTGTCCAGCATCATCT-3′. Total RNA was prepared from cultured pre-BI cells and analyzed by RNase protection assay exactly as previously described (24).
Pax5 (BSAP) Is Essential for Early B Cell Development before the Pre-BCR Stage.
Based on the expression of cell surface markers, we have recently demonstrated that B cell development is arrested in the bone marrow of Pax5 mutant mice (24) at a similar pro-B (pre-BI) cell stage as in mice that are deficient in one of the components of the pre-BCR (μMT [reference 36], λ5 [reference 36], and Igβ [reference 5]) or the V(D)J rearrangement machinery (RAG1 [reference 9] and RAG2 [reference 7]). Moreover, Pax5-deficient pre-BI cells are essentially unable to synthesize the Igμ protein, an important constituent of the pre-BCR, due to an ∼50-fold reduction of the VH-to-DHJH recombination frequency at the IgH locus (24). The inability to form a functional pre-BCR could therefore explain the early B cell developmental block observed in Pax5 mutant mice. This hypothesis makes the clear prediction that expression of a functionally rearranged Igμ transgene in Pax5 mutant mice should result in the formation of the pre-BCR, thus traversing this important checkpoint and advancing B cell development to the pre-BII cell stage. To test this hypothesis, we have introduced a rearranged murine Igμ transgene, which directs expression of a membrane-bound Igμ protein under the control of a VH gene promoter (28) into Pax5 (−/−) mice. As the chosen Igμ transgene has not yet been used for similar experiments, we have also tested its ability to guide B cell development to the pre-BII cell stage in RAG2-deficient mice. The transition from the pre-BI to the pre-BII cell stage is known to be accompanied by the downregulation of the early markers CD43 and c-kit, by the initiation of CD2 and CD25 expression, and by an increase in the total B cell number (9, 10, 37). B lymphocytes from RAG2 (−/−) bone marrow lacking or containing the Igμ transgene were compared by flow cytometric analysis (Fig. 1), demonstrating that the synthesis of CD43 and c-kit was indeed downregulated, the expression of CD2 and CD25 was initiated, and the number of B220+ cells was increased by about twofold in the presence of the transgene. In marked contrast, the B lymphocyte number and cell surface phenotype did not change in the bone marrow of Pax5 (−/−) mice irrespective of the presence or absence of the Igμ transgene (Fig. 1). Hence, the Pax5 and RAG2 gene mutations clearly differ, as the presence of a rearranged Igμ transgene is unable to rescue the early B cell developmental block in Pax5-deficient mice in contrast to RAG2-deficient mice.
Possible trivial explanations for the failure of the Igμ transgene to induce the pre-B cell transition could be that Pax5 itself is involved in the transcriptional control of the transgene or that B cell development is arrested before the initiation of transgene expression in Pax5 mutant mice. To investigate these possibilities, we have analyzed the presence of cytoplasmic Igμ protein in c-kit+ B220+ pre-BI cells of Pax5-deficient bone marrow (Fig. 2 A). No cytoplasmic Igμ protein could be detected by intracellular staining in Pax5 (−/−) pre-BI cells in agreement with the fact that the VH-to-DHJH recombination is drastically reduced in these cells (24). In contrast, the Igμ protein was expressed in the majority of Pax5 (−/−) pre-BI cells carrying the transgene. We therefore conclude that early expression of a rearranged Igμ transgene is not sufficient to trigger the pre-B cell transition in Pax5 mutant mice.
The mb-1 gene coding for Igα was recently shown to be a direct BSAP (Pax5) target whose expression is reduced ∼10-fold in Pax5-deficient pre-BI cells compared with wild-type cells (26). In addition to the Igμ protein, Igα is therefore a second component of the pre-BCR that is expressed under the control of Pax5. As the heterodimer consisting of the proteins Igα and Igβ constitutes the signal transducing unit of the pre-BCR (2), it is conceivable that the reduced Igα expression in Pax5-deficient pre-BI cells prevents the formation of a functional pre-BCR even in the presence of a rearranged Igμ transgene. To address this question, we have introduced a chimeric Igμ–Igβ transgene (16) into the Pax5 (−/−) background. The Igμ component of this transgene codes for a membrane-bound Ig with two transmembrane mutations (Y587V, S588V) which prevent its normal association with the Igα–Igβ dimer (27). The cytoplasmic domain of the fusion protein is encoded by Igβ and directly mediates signaling independent of the presence of endogenous Igα or Igβ proteins (27). Furthermore, the chimeric Igμ–Igβ receptor was shown to efficiently activate transition to the pre-BII cell stage and to induce allelic exclusion at the IgH locus in RAG-deficient mice (16). Hence, signaling of this chimeric receptor should be independent of the reduced expression levels of both Igα and Igμ proteins that are observed in Pax5-deficient mice. Nevertheless, the chimeric Igμ–Igβ gene was unable to advance B cell development in the bone marrow of Pax5 mutant mice, since its presence neither altered the expression of cell surface markers nor increased the number of B220+ cells (Fig. 3,A). However, the Igμ–Igβ fusion protein was expressed in pre-BI cells regardless of the Pax5 genotype (Fig. 3 B). Together, these in vivo data indicate that expression of the pre-BCR is not sufficient to rescue the early B cell developmental block in Pax5-deficient mice. Hence, the Pax5 mutation appears to arrest B lymphopoiesis at an early stage that is not responsive to pre-BCR signaling.
The survival of B cell precursors is controlled by differential expression of the antiapoptotic genes bcl-2 and bcl-xL during B lymphopoiesis (38, 39). Interestingly, the bcl-xL but not the bcl-2 gene is consistently expressed at a 10-fold lower level in Pax5-deficient pre-BI cells compared with wild-type cells, although this downregulation was shown to be an indirect consequence of the absence of Pax5 (26). In agreement with this finding, the pre-BI cells of Pax5 mutant bone marrow proved to be ultrasensitive to growth factor withdrawal, as they rapidly undergo apoptosis ex vivo in the absence of survival signals emanating from the IL-7 receptor (data not shown). In this context it is interesting to note that the expression of a bcl-2 transgene was previously shown to promote B cell development in scid mice (40) that also exhibit a defect in V(D)J recombination of Ig genes (for review see reference 41). Hence, we investigated the possibility that sustained cell survival may also rescue the early developmental block in Pax5-deficient bone marrow. For this purpose, the same Eμ-bcl-2-36 transgenic mouse, carrying a human bcl-2 cDNA under the control of the IgH Eμ enhancer (29), was crossed with Pax5 mutant mice. Expression of the bcl-2 transgene in Pax5 (−/−) pre-BI cells was demonstrated by cytoplasmic staining with an anti–human Bcl-2 antibody as well as by its ability to completely block apoptosis upon IL-7 withdrawal (data not shown). Nevertheless, the bcl-2 transgene was unable to advance B cell development to the pre-BII cell stage, as no CD43− B220+ B lymphocytes were observed in the bone marrow of bcl-2 transgenic, Pax5 (−/−) mice (Fig. 2 B). Instead, deregulated bcl-2 expression led to a modest increase in CD43+ B220+ pre-BI cells similar to the situation observed in RAG2 mutant mice carrying a bcl-2 transgene (42). Therefore, these data demonstrate that blocking apoptosis is not sufficient to promote B cell development in Pax5 mutant mice.
Stable Expression of the Pre-BCR and Absence of its Normal Signaling Response in Igμ Transgenic, Pax5-deficient Pre-BI Cells.
Expression of a functionally rearranged Igμ chain has previously been shown to alter the IL-7 responsiveness of precursor B cells in wild-type and RAG2 mutant mice (10). The proliferative response to IL-7 was considerably decreased in bone marrow cells of Igμ transgenic mice, thus preventing the establishment of long-term pre-BI cell cultures (10). One possible reason for this phenomenon may be the downregulation of c-kit expression in response to pre-BCR activation (33, 37), which eliminates an essential costimulatory signal for IL-7–dependent proliferation of B lymphoid precursor cells (43). To further study the function of the pre-BCR, we have established pre-BI cell cultures from bone marrow of Pax5-deficient mice carrying an Igμ(-Igβ) transgene. These pre-BI cells were cultured in the presence of stromal ST2 cells and IL-7, and their long-term proliferation potential was assessed after 1 mo of in vitro culture. Surprisingly, Pax5-deficient pre-BI cells could be efficiently established and maintained even in the presence of transgenic Igμ or chimeric Igμ–Igβ proteins (Table 1). In contrast, no pre-BI cell cultures with long-term proliferation capacity were obtained from homozygous or heterozygous RAG2 mutant mice carrying an Igμ transgene, as previously described (10). Thus, these data indicate that expression of the Igμ protein does not interfere with the proliferation potential of Pax5-deficient pre-BI cells in contrast to control B lymphocytes.
Given the possibility to grow Igμ transgenic, Pax5 (−/−) precursor cells, we next investigated whether these cells could assemble the pre-BCR on their surface. As shown by flow cytometric analysis, Pax5-deficient pre-BI cells containing or lacking the Igμ transgene expressed a similar level of the surrogate light chain λ5 on their surface (Fig. 4,A). In contrast, the Igμ protein was only found on the transgenic pre-BI cells. Furthermore, staining with a monoclonal antibody (SL156), which recognizes a conformational epitope present on the surrogate light chain-Igμ complex of the pre-BCR (33), demonstrated that the Igμ protein was part of the pre-BCR (Fig. 4 A). Three conclusions can be drawn from these data. First, the pre-BCR is stably expressed on the surface of Igμ transgenic, Pax5 (−/−) pre-BI cells despite the fact that the pre-BCR is only transiently expressed and rapidly internalized on wild-type precursor B cells (33, 44, 45). Second, the surrogate light chains are expressed at normal levels on transgenic, Pax5 (−/−) pre-BI cells, although their expression is usually downregulated in response to pre-BCR signaling (9, 10, 37, 38, 44). Third, the Igα protein is known to be essential for cell surface transport of Igs (46, 47), and yet the 10-fold lower mb-1 expression in Pax5-deficient pre-BI cells (26) seems to provide sufficient Igα protein for pre-BCR formation.
The expression of the TdT gene is rapidly downregulated during the pre-B cell transition in response to expression of a functionally rearranged Igμ protein (37, 38, 48). The TdT gene is therefore considered to be a downstream target in the signaling cascade initiated by the pre-BCR (48). As shown by RNase protection analysis, the level of TdT transcripts was similar in Pax5-deficient pre-BI cells regardless of the presence of the Igμ transgene (Fig. 4 B, lanes 2 and 3). In summary, the different results obtained with cultured pre-BI cells all demonstrate that the pre-BCR is unable to elicit its normal signaling response in the absence of Pax5 function.
The transcription factor Pax5 (BSAP) is involved in the control of VH-to-DHJH recombination and in the transcriptional regulation of the mb-1 gene, which results in reduced expression of the two pre-BCR components, Igμ and Igα, in Pax5-deficient pre-BI cells (24, 26). Here we have demonstrated that complementation of these deficiencies by the expression of Igμ and Igμ–Igβ transgenes is not sufficient to initiate the pre-B cell transition in Pax5 mutant mice. Hence, the inability to form a pre-BCR cannot be the cause of the early B cell developmental block in mice lacking Pax5. Instead, the absence of Pax5 arrests B cell development by a different mechanism compared with mice which lack a component of the pre-BCR (mIgμ [reference 3], λ5 [reference 4], or Igβ [reference 5]) or of the V(D)J recombination machinery (RAG1 [reference 6], RAG2 [reference 7], or DNA-PK [reference 8]). Consistent with this conclusion, the lack of Pax5 or RAG2 function has opposite effects on the in vitro differentiation potential of B lymphocytes. Pre-BI cells of RAG2 mutant mice efficiently differentiate ex vivo to the mature B cell stage upon stimulation with IL-4 and anti-CD40 antibodies, which by-passes in vitro the requirement of Ig gene rearrangements for further development (49). In contrast, Pax5 mutant pre-BI cells entirely fail to differentiate under the same in vitro conditions, further demonstrating a strict dependency of early B lymphopoiesis on Pax5 (Nutt, S.L., unpublished data).
It has been notoriously difficult to demonstrate expression of the pre-BCR on the surface of precursor B cells (33, 44), which reflects both a slow, inefficient cell surface transport and rapid, tyrosine phosphorylation–dependent internalization of this receptor (2, 45). Quite in contrast, we have now observed stable expression of the pre-BCR on the surface of Igμ transgenic, Pax5-deficient pre-BI cells. Interestingly, the constitutive cell surface expression of the pre-BCR correlates with the absence of normal signaling responses. The transgenic, Pax5-deficient pre-BI cells neither lost their long-term proliferation potential in the presence of IL-7 and stromal cells nor did they downregulate expression of the TdT or surrogate light chain genes, which are normal responses to pre-BCR signaling in wild-type precursor B cells (9, 10, 37, 38, 44, 48). Therefore, it is conceivable that Pax5 may either regulate the expression of an essential component of the signal transduction cascade or act in the nucleus as the critical mediator of pre-BCR signaling. Stimulation of the BCR is known to result in the phosphorylation and association of the Igα– Igβ heterodimer with the protein-tyrosine kinases Lyn, Fyn, Blk, Btk, and Syk (50–53). Moreover, the Syk kinase has been shown to play an important role in pre-BCR signaling (54, 55). However, none of these tyrosine kinase genes is expressed under the control of Pax5, as shown by a comprehensive analysis of putative BSAP (Pax5) target genes (26). Hence, there is at present no evidence that Pax5 is involved in the expression of cytoplasmic signal transducers. Moreover, an exclusive role of Pax5 in mediating signal transduction of the pre-BCR seems unlikely for several reasons. First, Pax5 expression is already initiated at B lineage commitment long before the pre-BCR stage and thereafter is maintained at a rather constant level throughout B lymphopoiesis (21–23). Second, all our attempts have so far failed to demonstrate any alteration in the posttranslational modification pattern of BSAP (Pax5) in response to signal transduction (M. Busslinger, unpublished data). Third, the developmental arrest in Pax5 mutant mice is tight (25) rather than leaky as it would be expected, in analogy to the syk (−/−) mouse (54, 55), for a mutation in a downstream component of the signal transduction pathway. Last but not least, a role for Pax5 in the regulation of λ5, VpreB, or TdT has recently been excluded (26), although the expression of these genes is downregulated in response to pre-BCR signaling.
The mouse scid mutation affects the XRCC7 gene coding for the catalytic subunit of the DNA-PK, which is essential for V(D)J recombination and double-stranded DNA break repair (8, 41). The phenotype of the scid mouse is known to be leaky in contrast to the RAG mutations, as scid B lymphocytes are still able to generate DH-to-JH and VH-to-DHJH rearrangements at a very low frequency (41). Hence, the scid and Pax5 mutations appear to be comparable with regard to their low efficiency of Ig gene rearrangements and early B cell developmental block. However, expression of a bcl-2 transgene in scid mice results in the accumulation of almost normal numbers of B lymphocytes that express many markers of mature B cells (40, 56). Due to the increased life span, the early progenitor cells present in the bcl-2 transgenic scid bone marrow seem to have a higher probability to generate productive DH-to-JH rearrangements in reading frame 2 and thus to express the truncated Dμ protein that promotes maturation to later B cell stages (56). Interestingly, we have previously shown that DH-to-JH rearrangements occur relatively frequently in reading frame 2 in pre-BI cells of Pax5 mutant bone marrow (24). Nevertheless, expression of the same bcl-2 transgene fails to promote B cell development in Pax5-deficient mice, thus further demonstrating that the early arrest of B lymphopoiesis is neither caused by a rearrangement defect nor by the lack of a survival signal.
The inability of Igμ and bcl-2 transgenes to advance B cell development and the constitutive cell surface expression of the pre-BCR strongly argue that B lymphopoiesis is arrested in Pax5 mutant mice at an early stage that is not responsive to pre-BCR signaling in the absence of Pax5 function. Consistent with this notion, the cell surface marker BP-1, which is specifically expressed on late pro-B (pre-BI) cells (57), is absent on bone marrow cells of Pax5-deficient mice (24). Therefore, it appears that Pax5 controls a critical step between initial B lineage commitment and the pre-BCR stage of adult B lymphopoiesis. In this context it is interesting to note that the interruption of Ras signaling also arrests early B cell development well before the pre-BCR stage (58). Our analysis of Pax5-deficient pre-BI cells has recently demonstrated a pleiotropic role of the transcription factor BSAP (Pax5) in gene regulation during early B lymphopoiesis (26). Hence, it will be a challenge for the future to identify the critical, and thus far unknown, BSAP target gene(s) that mediates the Pax5-dependent control of early B cell development.
We thank F. Alt (Harvard Medical School, Boston, MA) for providing the RAG2-deficient mouse; T. Imanishi-Kari (Tufts University, Boston, MA) for the transgenic M54 mouse; S. Cory (Walter and Eliza Hall Institute, Melbourne, Australia) for the Eμ-bcl2-36 strain; M. Nussenzweig (The Rockefeller University, New York) for the mIgμ–Igβ (YS:VV) mouse and anti-Igβ antiserum; T. Rolink (Basel Institute for Immunology, Switzerland) for monoclonal antibodies; and P. Steinlein for help with flow cytometric analysis.
This work was supported by the Research Institute of Molecular Pathology, and in part by a grant from the Austrian Industrial Research Promotion Fund.
Abbreviations used in this paper
Claire Thévenin's present address is Department of Medical and Molecular Parasitology, New York University Medical Center, New York, NY 10016.
Address correspondence to Meinrad Busslinger, Research Institute of Molecular Pathology, Dr. Bohr-Gasse 7, A-1030 Vienna, Austria. Phone: 43-1-797-30-452; Fax: 43-1-798-71-53; E-mail: email@example.com